InvestorsHub Logo
Followers 36
Posts 8921
Boards Moderated 0
Alias Born 08/10/2009

Re: KC01905 post# 5288

Monday, 05/20/2019 10:56:35 AM

Monday, May 20, 2019 10:56:35 AM

Post# of 6939
The meetings will discuss what the FDA is expecting from the BLA submission. Namely, what clinical data is to be presented and what the endpoint goals of the studies were and how they were met. It's a very good sign. It's essentially saying that the phase III trials are (near) complete and are considered a success by SESN.